Aspira Women's Health Registers 29.2M Shares for Resale by Investors

TL;DR

**AWHL's S-1 filing for 29.2 million resale shares is a massive overhang; expect significant dilution and downward pressure on the stock.**

AI Summary

Aspira Women's Health Inc. (AWHL) is filing an S-1 to register 29,226,527 shares of common stock for resale by existing accredited and institutional investors. The company will not receive any proceeds from these sales. This includes 5,915,850 shares from the conversion of $1,370,000 in Convertible Notes issued in March 2025, 11,848,177 shares underlying Amended and Restated March 2025 Warrants with an exercise price of $0.35 per share, 6,550,000 shares issued in a September 2025 private placement, and 4,912,500 shares underlying September 2025 Warrants with an exercise price of $0.75 per share. AWHL is focused on AI-powered diagnostic tests for gynecologic diseases, including ovarian cancer with its OvaSuite tests, and is developing ENDOinform for endometriosis, a market affecting over 6.5 million women in the U.S. The company expanded its OvaWatch test features in Q2 2024, increasing its addressable market tenfold from 200,000-400,000 to 2-4 million tests per year.

Why It Matters

This S-1 filing signals a significant potential dilution event for existing Aspira Women's Health (AWHL) shareholders, as nearly 30 million shares are being registered for resale by selling stockholders, with no proceeds going to the company. For investors, this could exert downward pressure on the stock price, which closed at $0.52 on September 29, 2025, potentially impacting market capitalization and investor confidence. The company's strategic focus on expanding its diagnostic test market, particularly with the OvaWatch test's tenfold market increase to 2-4 million tests annually and the development of ENDOinform for endometriosis, positions it in a competitive and growing healthcare diagnostics sector. However, the immediate impact of this large share registration on market dynamics and AWHL's ability to raise future capital will be closely watched.

Risk Assessment

Risk Level: high — The filing explicitly states, "Investing in our securities is highly speculative and involves a high degree of risk." The registration of 29,226,527 shares for resale by selling stockholders, from which the company will receive no proceeds, presents a substantial dilution risk. Furthermore, the company's common stock is listed on the OTCQB Market, which typically implies higher volatility and lower liquidity compared to major exchanges.

Analyst Insight

Investors should exercise extreme caution and consider the significant potential for dilution and downward price pressure due to the large volume of shares registered for resale. Current shareholders might consider re-evaluating their position, while prospective investors should await clarity on how the market absorbs this influx of shares before making any investment decisions.

Key Numbers

• 29,226,527 — Shares of Common Stock (Total shares registered for resale by Selling Stockholders, indicating potential dilution.)
• $1.37M — Convertible Notes (Aggregate principal amount of Convertible Notes issued in March 2025, which have since converted into shares.)
• 5,915,850 — Shares from Convertible Notes (Shares issued upon conversion of Convertible Notes, contributing to the resale pool.)
• 11,848,177 — Shares underlying Amended and Restated March 2025 Warrants (Shares that can be exercised and sold by March 2025 Purchasers.)
• 6,550,000 — Shares from September 2025 Purchase Agreement (Shares directly issued in the September 2025 private placement.)
• 4,912,500 — Shares underlying September 2025 Warrants (Shares that can be exercised and sold by September 2025 Purchasers.)
• $0.52 — Closing Stock Price (Closing price on OTCQB on September 29, 2025, providing a benchmark for the resale shares.)
• 2M-4M — Annual Addressable Market for Tests (Increased addressable market for OvaSuite tests after OvaWatch expansion in Q2 2024, a tenfold increase.)
• 6.5M — Women affected by Endometriosis in US (Size of the target market for the company's ENDOinform development program.)
• $0.35 — Amended March 2025 Warrants Exercise Price (Updated exercise price for a significant portion of the registered warrants.)

Key Players & Entities

• Aspira Women's Health Inc. (company) — Registrant and issuer of securities
• Michael Buhle (person) — Chief Executive Officer and Chief Commercial Officer
• J. Eric Johnson (person) — Legal counsel from Winston & Strawn LLP
• Winston & Strawn LLP (company) — Legal counsel for the registrant
• Securities and Exchange Commission (regulator) — Regulatory body for the S-1 filing
• $1,370,000 (dollar_amount) — Aggregate principal amount of Senior Secured Convertible Promissory Notes issued in March 2025
• $0.001 (dollar_amount) — Par value per share of Common Stock
• $0.52 (dollar_amount) — Closing price per share of Common Stock on OTCQB on September 29, 2025
• $0.35 (dollar_amount) — Exercise price per share for Amended and Restated March 2025 Warrants
• $0.75 (dollar_amount) — Exercise price per share for September 2025 Warrants

FAQ

Risk Factors

• Limited Market Liquidity on OTCQB [high — market]: The company's common stock is traded on the OTCQB, a less regulated market with lower standards than national exchanges like NYSE or Nasdaq. This can lead to increased volatility, potential for trading abuses, and difficulty for broker-dealers to recommend the stock due to FINRA suitability rules for low-priced securities, potentially depressing the stock price.
• Potential Dilution from Resale Shares [medium — financial]: The S-1 registers 29,226,527 shares for resale by existing investors, including shares from convertible notes, warrants, and private placements. This large volume of shares becoming available for sale could exert downward pressure on the stock price.
• Reliance on SEC Filings for Risk Disclosure [medium — regulatory]: The company directs investors to review risk factors in its Form 10-K and 10-Q filings, as well as this S-1. This reliance on incorporated documents means investors must consult multiple sources to fully understand the risks, and any adverse events or undisclosed risks could materially impact the business and stock price.

Industry Context

Aspira Women's Health operates in the diagnostic testing sector, specifically focusing on women's gynecologic diseases. The company leverages AI for its diagnostic solutions, aiming to address significant unmet needs in areas like ovarian cancer and endometriosis. The market for these diagnostics is substantial, with millions of women affected by these conditions in the U.S.

Regulatory Implications

As a company in the healthcare and diagnostics space, Aspira Women's Health is subject to stringent regulatory oversight from bodies like the FDA. The S-1 filing itself is a regulatory requirement for public offerings. The company's reliance on SEC filings for risk disclosure means adherence to disclosure rules is critical.

What Investors Should Do

1. Monitor OTCQB Trading Activity
2. Assess Dilution Impact
3. Evaluate Market Expansion Claims
4. Review Incorporated SEC Filings

Key Dates

• 2025-03-01: Issuance of Convertible Notes — These notes converted into 5,915,850 shares, contributing to the current resale registration.
• 2025-09-01: September 2025 Private Placement — Resulted in the issuance of 6,550,000 shares, which are part of the resale pool.
• 2024-06-30: OvaWatch Test Feature Expansion — Expanded the addressable market for OvaSuite tests tenfold, indicating product development progress and market opportunity.

Glossary

S-1 Filing

A registration statement filed with the U.S. Securities and Exchange Commission (SEC) by companies planning to offer securities to the public. It contains detailed information about the company's business, financial condition, and the securities being offered. (This document is the primary source of information for investors regarding the resale of shares and the company's current status.)

Convertible Notes

Debt instruments that can be converted into a predetermined amount of equity (common stock) at the option of the noteholder. (The conversion of $1.37M in convertible notes into 5,915,850 shares is a key component of the shares being registered for resale.)

Warrants

Securities that give the holder the right, but not the obligation, to purchase a company's stock at a specified price (exercise price) within a certain timeframe. (A significant number of shares (11,848,177 and 4,912,500) are registered for resale underlying these warrants, representing potential future dilution.)

OTCQB

An over-the-counter quotation service for early-stage and developing companies. It is less regulated than major stock exchanges. (The company's stock trades on the OTCQB, which presents specific risks related to liquidity and price volatility.)

FINRA

Financial Industry Regulatory Authority, a self-regulatory organization that oversees broker-dealers in the United States. (FINRA's sales practice rules can impact the ability of broker-dealers to recommend and facilitate trading of the company's low-priced securities.)

Year-Over-Year Comparison

This S-1 filing focuses on the registration of shares for resale by existing investors and does not involve the company raising new capital. Therefore, direct comparisons of revenue growth, margin changes, or new risks from a previous S-1 filing are not applicable. The primary focus is on the potential impact of the large volume of shares becoming available for trading on the OTCQB.

Key Financial Figures

• $0.001 — ”) of common stock, par value of $0.001 per share (the “ Common Stock &rd
• $1,370,000 — d sold an aggregate principal amount of $1,370,000 of Senior Secured Convertible Promissor
• $0.25 — which are exercisable for five years at $0.25 per share for the first 24 months after
• $0.50 — the first 24 months after issuance and $0.50 per share thereafter (the “ March
• $0.35 — pplicable to the March 2025 Warrants to $0.35 per share and removed the ability to ca
• $0.45 — of Common Stock at a purchase price of $0.45 per share of Common Stock, which are im
• $0.75 — e upon issuance at an exercise price of $0.75 per share and have a term of exercise e
• $0.52 — re of our Common Stock on the OTCQB was $0.52. We are a “smaller reporting com
• $700 million — res held by non-affiliates is less than $700 million and our annual revenue was less than $1
• $100 million — on and our annual revenue was less than $100 million during the most recently completed fisc
• $7,831,237 — e holders of the Warrants, estimated at $7,831,237. See “ Use of Proceeds ” fo
• $0.98 — th a weighted average exercise price of $0.98 per share; 1,852,045 shares of Common
• $1.19 — th a weighted average exercise price of $1.19 per share; and 2,052,560 shares of Co

Filing Documents

• forms-1.htm (S-1) — 274KB
• ex5-1.htm (EX-5.1) — 13KB
• ex23-1.htm (EX-23.1) — 4KB
• ex107.htm (EX-FILING FEES) — 28KB
• image_001.jpg (GRAPHIC) — 7KB
• ex5-1_001.jpg (GRAPHIC) — 6KB
• 0001493152-25-016373.txt ( ) — 460KB
• ex107_htm.xml (XML) — 6KB

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 14 SELLING STOCKHOLDERS 17 PLAN OF DISTRIBUTION 18 LEGAL MATTERS 22 EXPERTS 22 WHERE YOU CAN FIND MORE INFORMATION 22 INCORPORATION OF DOCUMENTS BY REFERENCE 23 i ABOUT THIS PROSPECTUS You should carefully read this prospectus before deciding to invest in our securities. We have not authorized anyone to provide you with additional information or information different from that contained or incorporated by reference in this prospectus filed with the Securities and Exchange Commission (the “ SEC ”). We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. The Selling Stockholders are offering to sell, and seeking offers to buy, our securities only in jurisdictions where offers and sales are permitted. The information contained in this prospectus, or any document incorporated by reference in this prospectus, is accurate only as of the date of those respective documents, regardless of the time of delivery of this prospectus or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. The information provided or incorporated by reference in this prospectus contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. We obtained the industry and market data in this prospectus or in the documents incorporated by reference into this prospectus from our own research as well as from industry and general publications, surveys and studies conducted by third parties. This data involves a number of assumptions and limitations and contains projections and estimates of the future performance of the industry in which we operate that are subject to a high degree of uncertainty, including those discussed in “ Risk Factors .” We caution you not to give undue weight to su

Use of Proceeds

Use of Proceeds We will not receive any proceeds from the sale of the Resale Shares by the Selling Stockholders. Upon the exercise of the Amended and Restated 2025 Warrants or the September 2025 Warrants by payment of cash, we will receive the nominal cash exercise price paid by the holders of the Warrants, estimated at $7,831,237. See “ Use of Proceeds ” for a more complete description.

Risk Factors

Risk Factors Investing in our securities is highly speculative and involves a high degree of risk. See “ Risk Factors ” beginning on page 7 of this prospectus, and the other information included or incorporated by reference in this prospectus for a discussion of factors you should consider carefully before deciding to invest in our securities. OTC Symbol for our Common Stock “AWHL” (1) The number of shares of our Common Stock to be outstanding after this offering is based on 42,655,918 shares of Common Stock outstanding as of September 29, 2025, and excludes: 21,235,745 shares of Common Stock issuable upon exercise of warrants with a weighted average exercise price of $0.98 per share; 1,852,045 shares of Common Stock issuable upon exercise of options with a weighted average exercise price of $1.19 per share; and 2,052,560 shares of Common Stock reserved for future issuance under our existing stock incentive plan. 6

RISK FACTORS

RISK FACTORS Investing in our Common Stock involves a high degree of risk. Before making an investment decision, you should carefully consider the risks described in the sections entitled “ Risk Factors ” in our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as filed with the SEC, which are incorporated herein by reference in their entirety, as well as any amendment or updates to our risk factors reflected in subsequent filings with the SEC, including any amendment or supplement to this prospectus or any report incorporated herein by reference. Our business, financial condition, results of operations or prospects could be materially adversely affected by any of these risks. The trading price of our securities could decline due to any of these risks, and you may lose all or part of your investment. This prospectus and the documents incorporated herein by reference also contain forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks mentioned elsewhere in this prospectus. For more information, see the below section “ Where You Can Find Additional Information .” Please also read carefully the above section “ Information Regarding Forward-Looking Statements .” Risks Related to our Common Stock Our Common Stock is currently traded on the OTCQB, which may have an unfavorable impact on our stock price and liquidity. Our Common Stock is currently quoted on the OTCQB. The OTCQB is significantly more limited market than the national securities exchanges such as the New York Stock Exchange, or Nasdaq stock exchange, and there are lower financial or qualitative standards that a company must meet to have its stock quoted on the OTCQB. OTCQB is an inter-dealer quotation system much less regulated than the major exchanges, and trading in our Common St

View Full Filing

View this S-1 filing on SEC EDGAR